A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment

Conditions

• Primary Immune Thrombocytopenia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

This study aims to evaluate treatment preferences of patients with Primary Immune Thrombocytopenia (ITP) in the United States (US) by conducting a preference elicitation survey.

Key Dates

First listed

Aug 25, 2026

Start date

Dec 8, 2025

Status verified

Aug 2026

Primary completion

Dec 15, 2026

Completion

Dec 15, 2026

Study Design

Enrollment

100 participants (estimated)

Arms

• Arm: ITP Cohort
  Adults with ITP in the US who are being treated in either 1L or 2L settings.

Primary Outcome Measure

Preference Weights for Treatment Attributes [ Time Frame: 1 Day ]

Central Contacts

• Novartis Pharmaceuticals
  +41613241111
  [email protected]
• Novartis Pharmaceuticals

Locations (1)

Find similar trials in East Hanover, NJ

Related Studies

• Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
  PHASE2 · Recruiting · Pfizer · Greenville, North Carolina